Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of December 2025 for Radiopharm Theranostics Limited, a foreign private issuer based in Australia. The report serves to disseminate a public notice issued to the Australian Securities Exchange on December 15, 2025, regarding clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change disclosed is the release of interim Phase 2b clinical data for the company's candidate RAD101. The data indicates that 92% of subjects achieved the primary endpoint.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the clinical milestone. The filing explicitly states that this report and its exhibits are not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated. No specific guidance, risk factors, or contingencies are detailed within the text of this specific Form 6-K.
Key Facts for Investor Verification
- Interim Phase 2b data for RAD101 shows a 92% achievement rate for the primary endpoint.
- The announcement was made to the Australian Securities Exchange on December 15, 2025.
- The full details of the clinical data are contained in Exhibit 99.1, which is attached to this filing.
- This document does not contain updated financial performance metrics.